At a glance
- Originator Nonindustrial source
- Class Antiplatelets
- Mechanism of Action Platelet aggregation inhibitors; Prostaglandin D2 receptor antagonists; Thromboxane B2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Thrombosis
Most Recent Events
- 05 Apr 2000 New profile
- 05 Apr 2000 Preclinical development for Thrombosis in South Korea (Unknown route)